Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
Cat . Non | Espèces | Description du produit | Structure | Pureté | Caractéristique |
---|---|---|---|---|---|
ZE5-V5221 | Ebolavirus | Ebolavirus EBOV (subtype Zaire, strain Kikwit-95) Envelope Glycoprotein (GP) Protein, His Tag |
|
||
BEP-V5220 | Ebolavirus | Ebolavirus BDBV (subtype Bundibugyo, strain Uganda 2007) Small/secreted Glycoprotein (sGP) Protein, His Tag |
|
||
ZE5-V5220 | Ebolavirus | Ebolavirus EBOV (subtype Zaire, strain Kikwit-95) Envelope Glycoprotein 1 (GP1) Protein, His Tag |
|
||
BEP-V5221 | Ebolavirus | Ebolavirus (subtype Bundibugyo, strain Uganda 2007) Envelope Glycoprotein 1 (GP1) Protein, His Tag |
|
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Ansuvimab | VRC-EBOMAB092-00-AB; MAb114; MAb-114 | Approved | National Institute Of Allergy And Infectious Diseases (Niaid), National Institute of Health, Islamabad | Ebanga | United States | Hemorrhagic Fever, Ebola | Ridgeback Biotherapeutics Lp | 2020-12-21 | Hemorrhagic Fever, Ebola | Details |
Atoltivimab/Maftivimab/Odesivimab | REGN3470-3471-3479; REGN-EB3 | Approved | Inmazeb | United States | Hemorrhagic Fever, Ebola | Regeneron Pharmaceuticals Inc | 2020-10-14 | Hemorrhagic Fever, Ebola | Details | |
Ansuvimab | VRC-EBOMAB092-00-AB; MAb114; MAb-114 | Approved | National Institute Of Allergy And Infectious Diseases (Niaid), National Institute of Health, Islamabad | Ebanga | United States | Hemorrhagic Fever, Ebola | Ridgeback Biotherapeutics Lp | 2020-12-21 | Hemorrhagic Fever, Ebola | Details |
Atoltivimab/Maftivimab/Odesivimab | REGN3470-3471-3479; REGN-EB3 | Approved | Inmazeb | United States | Hemorrhagic Fever, Ebola | Regeneron Pharmaceuticals Inc | 2020-10-14 | Hemorrhagic Fever, Ebola | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Porgaviximab/Larcaviximab/Cosfroviximab | c2G4-N; c4G7; c13C6 | Phase 3 Clinical | Mapp Biopharmaceutical, Public Health Agency Of Canada'S National Microbiology Laboratory | Hemorrhagic Fever, Ebola | Details |
MIL-77 | MIL-77 | Phase 1 Clinical | Beijing Mabworks Biotech Co Ltd, Zhejiang Hisun Pharmaceutical Co Ltd, Institute Of Basic Medicine Academy Of Military Medical Sciences | Hemorrhagic Fever, Ebola | Details |
Porgaviximab/Larcaviximab/Cosfroviximab | c2G4-N; c4G7; c13C6 | Phase 3 Clinical | Mapp Biopharmaceutical, Public Health Agency Of Canada'S National Microbiology Laboratory | Hemorrhagic Fever, Ebola | Details |
MIL-77 | MIL-77 | Phase 1 Clinical | Beijing Mabworks Biotech Co Ltd, Zhejiang Hisun Pharmaceutical Co Ltd, Institute Of Basic Medicine Academy Of Military Medical Sciences | Hemorrhagic Fever, Ebola | Details |
This web search service is supported by Google Inc.